In colorectal cancer, mRNA vaccine research is especially focused on people who still have circulating tumor DNA after surgery, a sign that microscopic disease may remain. Autogene cevumeran/BNT122/RO7198457 is being tested as an adjuvant approach to help the immune system recognize tumor neoantigens and reduce recurrence risk. This is Phase 2 research and should be framed as investigational. Several Phase 3 trials are advancing precision strategies. Adagrasib (MRTX849) plus cetuximab is being tested against chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C-mutated advanced disease. Pucotenlimab, an anti-PD-1 antibody, combined with CAPOX is in Phase 3 for locally advanced rectal cancer. Liquid biopsy approaches are active: a Phase 3 trial uses ctDNA to guide therapy decisions in metastatic disease, and mid-phase trials test ctDNA-guided surveillance and adjuvant chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → intensity in Stage III disease. Earlier-phase work includes the STAR15 immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → regimen combining a CXCR1/2 inhibitor with a vaccine and IL-15 agonist for metastatic colorectal cancer, the anti-CEACAM5 ADC M9140, ZEN003694 BET bromodomain inhibition added to capecitabine, and TROP2-directed CAR-NK cell therapy for peritoneal carcinomatosis. Watch-and-wait protocols after PD-1 inhibitors in MSI-high distal rectal cancer are being evaluated. Laboratory studies highlight roles for PI3K and MAPK pathway crosstalk, statin combinations with SREBP2 inhibitors, lysine lactylation in cell proliferation, and STK25-mediated cancer-associated fibroblast activation underlying cetuximab resistance.
Where the evidence stands
Standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → backbones, anti-VEGF and anti-EGFR antibodies, and immune checkpoint inhibition for MSI-high disease are firmly established. Targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → for BRAF V600E, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C, and HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → amplification have entered the metastatic setting, with more KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → combinations in late development. ctDNA-guided care, ADCs, and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → approaches for the much larger group of microsatellite stable tumors are in mid to late development. Many cellular and metabolic findings are still preclinical.
What this means for people affected
Most colorectal cancers are microsatellite stable and respond modestly to current immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →, which is the central unmet need. For the smaller MSI-high group, immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → has changed outcomes substantially. The expansion of biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-driven therapy means RAS, BRAF, HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →, and MSI testing are now expected at diagnosis of advanced disease. Liquid biopsy is emerging as a tool to personalize adjuvant decisions, and several Phase 3 trials may change practice in the next few years. Localized rectal cancer increasingly involves total neoadjuvant therapy strategies, and selected MSI-high rectal cancers may avoid surgery entirely if they respond completely to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →. Molecular testing and trial options are reasonable to discuss early when facing metastatic disease.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
ReviewSummary and analysis of existing published studies.Published: May 26, 2026
Link Between Oral and Gut Microbes and Colorectal Cancer
Researchers examined the connection between oral and gut microbes and colorectal cancer. They found that certain oral bacteria may contribute to CRC progression by altering the gut microecology. However, more research is needed to fully understand this relationship.
Why it matters: This finding could lead to new insights into the causes of colorectal cancer and potential targets for future treatments.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 25, 2026
Socioeconomic Status Affects Colorectal Cancer Surgery Outcomes
Researchers studied 476 patients who had colorectal cancer surgery in Germany between 2016 and 2023. They found that patients from wealthier areas were more likely to have emergency surgery and older age. Patients from poorer areas were more likely to be younger and have a higher body mass index.
Why it matters: This finding highlights potential differences in risk profiles for patients from different socioeconomic backgrounds.
◆ Notable findingA noteworthy finding, often from later-stage research, but below the higher significance thresholds.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: May 25, 2026
Cost-effectiveness of cancer treatment in China questioned
Researchers analyzed the cost-effectiveness of a cancer treatment called encorafenib in China. They compared it to standard care and found that it may not be worth the cost at current prices. This suggests that prices might need to be negotiated to make the treatment more affordable.
Why it matters: This finding could influence how cancer treatments are priced and made available to patients in China.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 25, 2026
COVID-19 Pandemic's Effect on Colorectal Cancer Rates
Researchers analyzed colorectal cancer rates in Bavaria before and during the COVID-19 pandemic. They found that rates decreased in the first year of the pandemic, but returned to expected levels by the third year. Early-stage cancers showed a persistent decline.
Why it matters: This study's findings may help researchers understand how the pandemic affected cancer rates and inform future research.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 24, 2026
Artesunate May Help Overcome Resistance to Cancer Treatment in Colorectal Cancer
Researchers tested how Artesunate affects colorectal cancer cells that are resistant to oxaliplatin, a common chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → drug. They found that Artesunate can induce a type of cell death called ferroptosis, which may help overcome resistance to oxaliplatin. However, more research is needed to confirm these findings.
Why it matters: This study highlights a potential new approach to treating colorectal cancer that is resistant to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →.
This study was conducted in lab experiments and has not been tested in humans.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 22, 2026
Comparing Treatments for High-Risk Rectal Cancer
Researchers compared two treatments for high-risk rectal cancer: one that combines chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and radiation, and one that uses chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → alone. They found that the combined treatment worked better for some patients, but also had more side effects. However, the survival rates were similar for both groups.
Why it matters: This study provides more information for doctors to consider when deciding which treatment is best for patients with high-risk rectal cancer.
Efficacy
The TNT group demonstrated a higher pathological complete response (pCR) rate compared to the NACT group (23.81% vs. 8.84%, p=0.007)
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 22, 2026
Ginger Compound Shows Promise in Fighting Colorectal Cancer
Researchers studied a compound called Gingerenone A, derived from ginger, to see if it could help prevent colorectal cancer. They tested it in lab experiments and in rats with cancer. They found that it may help slow down cancer growth by affecting two key pathways.
Why it matters: This finding could lead to new ways to prevent or treat colorectal cancer, a major global health challenge.
This study was conducted in lab experiments and in rats, so its results may not directly apply to humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 22, 2026
New Tool Helps Predict Colorectal Cancer Survival
Researchers used 101 machine learning methods to analyze data from 630 colorectal cancer patients. They found that a specific score, called the immune-related gene risk score, can help predict patient survival. This score is associated with immune cell activity in the tumor.
Why it matters: This finding could help doctors develop more personalized treatment plans for colorectal cancer patients.
Efficacy
The Ridge regression model demonstrated the most robust performance with a mean concordance index of 0.67.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 22, 2026
Rare Case of Pancreatic Metastasis from Colorectal Cancer
Researchers reported a rare case of pancreatic metastasis from colorectal cancer. A 70-year-old man with rectal cancer developed a cystic pancreatic lesion, which was confirmed to be metastatic. He underwent surgery and chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →.
Why it matters: This finding may help improve understanding and guide future care for patients with pancreatic metastases from colorectal cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 22, 2026
Immune Cells in Liver Tumors May Help Cancer Grow
Researchers studied liver tumors from people with colorectal cancer and found that certain immune cells in the tumors might be helping the cancer grow. They identified different types of immune cells in different parts of the tumors, and found that some of these cells were not working properly. This could be a reason why some treatments don't work as well as they should.
Why it matters: This finding could help scientists understand why some treatments for liver tumors don't work and how to make them more effective.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 22, 2026
New Model Predicts Colorectal Cancer Survival
Researchers analyzed data from over 400 colorectal cancer patients to identify genes that affect survival. They created a new model using this information to predict patient survival, which showed promising results in lab experiments.
Why it matters: This finding could help doctors make more accurate predictions about patient survival and plan treatment accordingly.
Efficacy
The AUC values for patient survival prediction during the 3-year, 3-6 year, and 6-year periods were nearly 1.00.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 22, 2026
Rare Cancer Type Masquerades as Inflammation in Young Man
Researchers reported a case of a man in his early 30s who had a rare type of rectal cancer that mimicked an inflammatory disease. The cancer, called signet ring cell carcinoma, was difficult to diagnose with superficial biopsies and standard tests. The diagnosis was only confirmed after surgery.
Why it matters: This finding highlights the challenges of diagnosing rare cancer types and the importance of considering alternative explanations for symptoms.
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
A Study Evaluating the Safety and Efficacy of Targeted TherapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
